Aug 32026 Upadacitinib for Immune Checkpoint InhibitorRelated Dermatitis This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.
